EU fails to confirm if women, young adults at higher clot risk from AstraZeneca shot By Reuters

0
33
© Reuters. FILE PHOTO: Vial labelled “AstraZeneca coronavirus disease (COVID-19) vaccine” placed on displayed EU flag is seen in this illustration picture taken March 24, 2021. REUTERS/Dado Ruvic/Illustration

(Reuters) – Europe’s drugs regulator said on Friday it could not confirm if women and young adults were at a higher risk of rare blood clots with low platelets following vaccination with AstraZeneca (NASDAQ:)’s COVID-19 vaccine after it studied available data.

Limitations in the way the data was collected meant that the European Medicines Agency could not identify any specific risk factor that made the condition, thrombosis with thrombocytopenia syndrome (TTS), more likely, it said https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-13-16-september-2021.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.